Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Bila M
San Francisco, California, United Statesbila.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
01
Overview
Bila is a biotechnology company focused on developing next-generation, long-acting therapies for the treatment and prevention of HIV. The company's lead programs utilize a novel mechanism of action targeting the HIV-1 capsid protein to inhibit viral replication. By focusing on ultra-long-acting formulations, Bila aims to reduce the dosing frequency for patients, potentially moving from daily pills to injections administered every few months. The company is leveraging expertise in medicinal chemistry and virology to address the limitations of current antiretroviral therapies.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Bila M.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bila M.